Reported Earnings • May 01
First quarter 2026 earnings released: EPS: CN¥0.062 (vs CN¥0.038 in 1Q 2025) First quarter 2026 results: EPS: CN¥0.062 (up from CN¥0.038 in 1Q 2025). Revenue: CN¥125.9m (up 21% from 1Q 2025). Net income: CN¥29.1m (up 63% from 1Q 2025). Profit margin: 23% (up from 17% in 1Q 2025). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Announcement • Apr 30
Shanghai MicroPort EP MedTech Co., Ltd., Annual General Meeting, May 20, 2026 Shanghai MicroPort EP MedTech Co., Ltd., Annual General Meeting, May 20, 2026, at 14:30 China Standard Time. Location: Building 3, Lane 1999, Zhangheng Road, Pudong New Area, Shanghai China New Risk • Apr 15
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 63% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company. Major Estimate Revision • Apr 08
Consensus EPS estimates fall by 15% The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from CN¥556.4m to CN¥534.8m. EPS estimate also fell from CN¥0.162 per share to CN¥0.138 per share. Net income forecast to grow 27% next year vs 30% growth forecast for Medical Equipment industry in China. Consensus price target of CN¥25.81 unchanged from last update. Share price rose 2.9% to CN¥24.60 over the past week. Buy Or Sell Opportunity • Mar 31
Now 20% overvalued Over the last 90 days, the stock has fallen 5.3% to CN¥21.92. The fair value is estimated to be CN¥18.26, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has grown by 80%. Revenue is forecast to grow by 65% in 2 years. Earnings are forecast to grow by 189% in the next 2 years. Announcement • Mar 30
Shanghai MicroPort EP MedTech Co., Ltd. to Report Q1, 2026 Results on Apr 30, 2026 Shanghai MicroPort EP MedTech Co., Ltd. announced that they will report Q1, 2026 results on Apr 30, 2026 Reported Earnings • Feb 12
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: CN¥0.11 (down from CN¥0.11 in FY 2024). Revenue: CN¥464.5m (up 12% from FY 2024). Net income: CN¥51.2m (down 1.8% from FY 2024). Profit margin: 11% (down from 13% in FY 2024). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 5.3%. Earnings per share (EPS) also missed analyst estimates by 24%. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Announcement • Dec 26
Shanghai MicroPort EP MedTech Co., Ltd. to Report Fiscal Year 2025 Results on Mar 31, 2026 Shanghai MicroPort EP MedTech Co., Ltd. announced that they will report fiscal year 2025 results on Mar 31, 2026 Buy Or Sell Opportunity • Oct 30
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 6.5% to CN¥23.19. The fair value is estimated to be CN¥19.18, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 74% in 2 years. Earnings are forecast to grow by 169% in the next 2 years. Reported Earnings • Oct 28
Third quarter 2025 earnings released: EPS: CN¥0.02 (vs CN¥0.052 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.02 (down from CN¥0.052 in 3Q 2024). Revenue: CN¥112.7m (up 22% from 3Q 2024). Net income: CN¥9.25m (down 63% from 3Q 2024). Profit margin: 8.2% (down from 27% in 3Q 2024). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Announcement • Sep 30
Shanghai MicroPort EP MedTech Co., Ltd. to Report Q3, 2025 Results on Oct 28, 2025 Shanghai MicroPort EP MedTech Co., Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025 Buy Or Sell Opportunity • Sep 08
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 23% to CN¥23.87. The fair value is estimated to be CN¥19.44, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 74% in 2 years. Earnings are forecast to grow by 93% in the next 2 years. Buy Or Sell Opportunity • Aug 11
Now 24% overvalued after recent price rise Over the last 90 days, the stock has risen 11% to CN¥23.60. The fair value is estimated to be CN¥19.07, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 72% in 2 years. Earnings are forecast to grow by 71% in the next 2 years. Announcement • Jun 30
Shanghai MicroPort EP MedTech Co., Ltd. to Report First Half, 2025 Results on Aug 27, 2025 Shanghai MicroPort EP MedTech Co., Ltd. announced that they will report first half, 2025 results on Aug 27, 2025 Announcement • May 27
Shanghai MicroPort EP MedTech Co., Ltd., Annual General Meeting, Jun 18, 2025 Shanghai MicroPort EP MedTech Co., Ltd., Annual General Meeting, Jun 18, 2025, at 14:30 China Standard Time. Location: 3F, Building 23, Lane 588, Tianxiong Road, Zhoupu Town, Pudong New Area, Shanghai China New Risk • May 06
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 24% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. This is currently the only risk that has been identified for the company. Buy Or Sell Opportunity • Apr 21
Now 24% overvalued after recent price rise Over the last 90 days, the stock has risen 17% to CN¥20.91. The fair value is estimated to be CN¥16.82, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 25% per annum. Earnings are also forecast to grow by 36% per annum over the same time period. Major Estimate Revision • Mar 28
Consensus revenue estimates decrease by 11% The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from CN¥597.1m to CN¥528.5m. EPS estimate unchanged from CN¥0.15 per share at last update. Medical Equipment industry in China expected to see average net income growth of 57% next year. Consensus price target broadly unchanged at CN¥24.37. Share price was steady at CN¥19.71 over the past week. Announcement • Mar 28
Shanghai MicroPort EP MedTech Co., Ltd. to Report Q1, 2025 Results on Apr 30, 2025 Shanghai MicroPort EP MedTech Co., Ltd. announced that they will report Q1, 2025 results on Apr 30, 2025 Reported Earnings • Feb 25
Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2024 results: EPS: CN¥0.11 (up from CN¥0.012 in FY 2023). Revenue: CN¥413.2m (up 26% from FY 2023). Net income: CN¥52.2m (up CN¥46.5m from FY 2023). Profit margin: 13% (up from 1.7% in FY 2023). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 5.7%. Earnings per share (EPS) exceeded analyst estimates by 29%. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Medical Equipment industry in China. Price Target Changed • Feb 07
Price target decreased by 11% to CN¥24.31 Down from CN¥27.40, the current price target is an average from 5 analysts. New target price is 26% above last closing price of CN¥19.25. Stock is down 15% over the past year. The company is forecast to post earnings per share of CN¥0.086 for next year compared to CN¥0.012 last year. Buy Or Sell Opportunity • Jan 02
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 15% to CN¥18.61. The fair value is estimated to be CN¥23.31, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 97% in 2 years. Earnings are forecast to grow by 196% in the next 2 years. Announcement • Dec 27
Shanghai MicroPort EP MedTech Co., Ltd. to Report Fiscal Year 2024 Results on Mar 28, 2025 Shanghai MicroPort EP MedTech Co., Ltd. announced that they will report fiscal year 2024 results on Mar 28, 2025 Announcement • Dec 10
Magbot Robotic Magnetic Navigation Ablation Catheter Receives Approval by China’s NMPA Stereotaxis and Shanghai MicroPort EP Medtech Co., Ltd. announced that the Magbot Magnetic Navigation Ablation Catheter has received regulatory approval from China’s National Medical Products Administration (NMPA). The Magbot Catheter is a single-use magnetic saline-irrigated radiofrequency ablation catheter designed and developed by MicroPort EP in collaboration with Stereotaxis. The catheter works exclusively and in tight conjunction with Stereotaxis’ robotic systems, including the recently NMPA-approved Genesis RMN, and MicroPort EP’s Columbus 3D EP Mapping System. Magbot incorporates advanced design features that substantially enhance the efficiency, effectiveness, and safety of robotic magnetic catheter ablation. Robotically navigated using low-intensity magnetic fields, the Magbot catheter is able to reach areas of the heart otherwise difficult to access with traditional methods and to maintain precise positioning and stability on cardiac anatomy with millimeter-level accuracy. Full integration with Columbus enables real-time location tracking and 3D cardiac modeling, allowing physicians to accurately record electrocardiographic data and pinpoint lesions for precise diagnosis and treatment of arrhythmias. A unique six-electrode design enhances safety during procedures by offering visibility of the catheter shaft without the need for fluoroscopy. Magbot has been approved by NMPA for the ablation of drug-resistant persistent atrial fibrillation, atrioventricular nodal reentrant tachycardia, and atrioventricular reentrant tachycardia. MicroPort EP will initiate commercial launch of Magbot in China through its existing sales team focused on the electrophysiology community. Stereotaxis shares in the proceeds from Magbot adoption. MicroPort EP is one of China’s leading medical device companies with a portfolio of cardiovascular medical devices designed to diagnose and treat arrythmias. Stereotaxis and MicroPort EP previously announced their collaboration in August 2021. Buy Or Sell Opportunity • Dec 03
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 14% to CN¥22.76. The fair value is estimated to be CN¥18.76, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 97% in 2 years. Earnings are forecast to grow by 196% in the next 2 years. Announcement • Nov 26
Stereotaxis Genesis Robotic System Achieves Regulatory Approval in China On November 25, 2024, Stereotaxis and Shanghai MicroPort EP Medtech Co., Ltd. announced regulatory approval of the Genesis RMN System by China’s National Medical Products Administration. This approval is a significant milestone, making available the latest advances in minimally-invasive robotic technology to physicians and patients in China. MicroPort EP is initiating full commercial launch of Genesis through its existing sales teams focused on the electrophysiology community. Approval of Genesis is a key element in a broader collaboration between Stereotaxis and MicroPort EP which entails the development, integration and commercialization of Stereotaxis’ robotic system, robotically-navigated catheters, and MicroPort EP’s Columbus 3D mapping system. MicroPort EP is one of China’s leading medical device companies with a portfolio of cardiovascular medical devices designed to diagnose and treat arrythmias. Stereotaxis and MicroPort EP previously announced their collaboration in August 2021. Genesis is the latest innovation in Robotic Magnetic Navigation technology. Robotic Magnetic Navigation introduces the benefits of robotic precision and safety to minimally-invasive endovascular procedures. The Genesis RMN System has FDA clearance and is CE marked, with systems across the United States and Europe having been used to treat thousands of patients. Major Estimate Revision • Oct 28
Consensus EPS estimates increase by 13%, revenue downgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from CN¥466.8m to CN¥446.7m. EPS estimate rose from CN¥0.075 to CN¥0.085. Net income forecast to grow 89% next year vs 58% growth forecast for Medical Equipment industry in China. Consensus price target down from CN¥27.40 to CN¥25.98. Share price rose 11% to CN¥21.50 over the past week. Reported Earnings • Oct 22
Third quarter 2024 earnings released: EPS: CN¥0.052 (vs CN¥0.02 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.052 (up from CN¥0.02 in 3Q 2023). Revenue: CN¥92.5m (down 1.5% from 3Q 2023). Net income: CN¥24.7m (up 164% from 3Q 2023). Profit margin: 27% (up from 10.0% in 3Q 2023). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Announcement • Sep 30
Shanghai MicroPort EP MedTech Co., Ltd. to Report Q3, 2024 Results on Oct 22, 2024 Shanghai MicroPort EP MedTech Co., Ltd. announced that they will report Q3, 2024 results on Oct 22, 2024 Buy Or Sell Opportunity • Sep 20
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 27% to CN¥16.80. The fair value is estimated to be CN¥21.08, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 37% over the last year. Meanwhile, the company has become profitable. Revenue is forecast to grow by 103% in 2 years. Earnings are forecast to grow by 435% in the next 2 years. New Risk • Sep 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Large one-off items impacting financial results. Reported Earnings • Aug 22
Second quarter 2024 earnings released: EPS: CN¥0.027 (vs CN¥0.025 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.027 (up from CN¥0.025 in 2Q 2023). Revenue: CN¥109.2m (up 21% from 2Q 2023). Net income: CN¥12.8m (up 12% from 2Q 2023). Profit margin: 12% (down from 13% in 2Q 2023). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Buy Or Sell Opportunity • Jul 31
Now 21% overvalued Over the last 90 days, the stock has fallen 14% to CN¥21.99. The fair value is estimated to be CN¥18.12, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue is forecast to grow by 97% in 2 years. Earnings are forecast to grow by 375% in the next 2 years. Buy Or Sell Opportunity • Jul 11
Now 21% overvalued Over the last 90 days, the stock has fallen 9.6% to CN¥21.76. The fair value is estimated to be CN¥17.95, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue is forecast to grow by 97% in 2 years. Earnings are forecast to grow by 375% in the next 2 years. Announcement • Jun 29
Shanghai MicroPort EP MedTech Co., Ltd. to Report First Half, 2024 Results on Aug 22, 2024 Shanghai MicroPort EP MedTech Co., Ltd. announced that they will report first half, 2024 results on Aug 22, 2024 Board Change • May 31
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Dennis Yizheng was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • May 25
Shanghai MicroPort EP MedTech Co., Ltd., Annual General Meeting, Jun 18, 2024 Shanghai MicroPort EP MedTech Co., Ltd., Annual General Meeting, Jun 18, 2024, at 14:30 China Standard Time. Location: 1F, Building 15, Lane 588, Tianxiong Road, Zhoupu Town, Pudong New Area, Shanghai China Reported Earnings • Apr 26
First quarter 2024 earnings released: EPS: CN¥0.009 (vs CN¥0.02 loss in 1Q 2023) First quarter 2024 results: EPS: CN¥0.009 (up from CN¥0.02 loss in 1Q 2023). Revenue: CN¥89.2m (up 71% from 1Q 2023). Net income: CN¥4.17m (up CN¥13.5m from 1Q 2023). Profit margin: 4.7% (up from net loss in 1Q 2023). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Major Estimate Revision • Apr 05
Consensus EPS estimates increase by 23% The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate increased from CN¥0.061 to CN¥0.076. Revenue forecast steady at CN¥466.0m. Net income forecast to grow 516% next year vs 32% growth forecast for Medical Equipment industry in China. Consensus price target up from CN¥24.93 to CN¥26.97. Share price fell 7.5% to CN¥24.06 over the past week. Reported Earnings • Apr 01
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CN¥0.012 (up from CN¥0.007 in FY 2022). Revenue: CN¥329.2m (up 27% from FY 2022). Net income: CN¥5.69m (up 91% from FY 2022). Profit margin: 1.7% (up from 1.1% in FY 2022). Revenue missed analyst estimates by 3.4%. Earnings per share (EPS) also missed analyst estimates by 68%. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Announcement • Mar 29
Shanghai MicroPort EP MedTech Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024 Shanghai MicroPort EP MedTech Co., Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024 Reported Earnings • Feb 27
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CN¥0.012 (up from CN¥0.007 in FY 2022). Revenue: CN¥329.2m (up 27% from FY 2022). Net income: CN¥5.47m (up 84% from FY 2022). Profit margin: 1.7% (up from 1.1% in FY 2022). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 3.4%. Earnings per share (EPS) also missed analyst estimates by 69%. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Major Estimate Revision • Nov 02
Consensus EPS estimates fall by 16% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from CN¥344.6m to CN¥340.6m. EPS estimate also fell from CN¥0.052 per share to CN¥0.044 per share. Net income forecast to grow 253% next year vs 41% growth forecast for Medical Equipment industry in China. Consensus price target of CN¥24.34 unchanged from last update. Share price rose 8.6% to CN¥22.00 over the past week. Reported Earnings • Oct 27
Third quarter 2023 earnings released: EPS: CN¥0.02 (vs CN¥0.003 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.02 (up from CN¥0.003 in 3Q 2022). Revenue: CN¥93.9m (up 34% from 3Q 2022). Net income: CN¥9.36m (up CN¥8.15m from 3Q 2022). Profit margin: 10.0% (up from 1.7% in 3Q 2022). Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in China. New Risk • Aug 26
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 37% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (37% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (6.3% average weekly change). Reported Earnings • Aug 19
Second quarter 2023 earnings released: EPS: CN¥0.025 (vs CN¥0.004 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.025 (up from CN¥0.004 in 2Q 2022). Revenue: CN¥90.0m (up 36% from 2Q 2022). Net income: CN¥11.5m (up CN¥9.83m from 2Q 2022). Profit margin: 13% (up from 2.5% in 2Q 2022). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Reported Earnings • Mar 29
Full year 2022 earnings: EPS misses analyst expectations Full year 2022 results: EPS: CN¥0.007 (up from CN¥0.03 loss in FY 2021). Revenue: CN¥260.3m (up 37% from FY 2021). Net income: CN¥2.97m (up CN¥14.9m from FY 2021). Profit margin: 1.1% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 30%. Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Reported Earnings • Feb 22
Full year 2022 earnings: EPS misses analyst expectations Full year 2022 results: EPS: CN¥0.007 (up from CN¥0.03 loss in FY 2021). Revenue: CN¥260.3m (up 37% from FY 2021). Net income: CN¥2.97m (up CN¥14.9m from FY 2021). Profit margin: 1.1% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 30%. Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Reported Earnings • Oct 27
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: CN¥70.0m (up 41% from 3Q 2021). Net income: CN¥1.22m (up CN¥5.37m from 3Q 2021). Profit margin: 1.7% (up from net loss in 3Q 2021). 
